Artwork

ASCO 2025 Plenary: SERENA-6

Two Onc Docs

11 subscribers

published

iconShare
 
Manage episode 490535264 series 3421368
Content provided by Sam and Karine. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sam and Karine or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

This week’s episode will be focusing on one of the 2025 plenary sessions: SERENA-6, Camizestrant, a novel selective estrogen receptor degrader (SERD) + CDK 4/6i for tx of emergent ESR1 during 1L endocrine-based therapy + ahead of progression in stage 4 HR+/Her-2 negative breast cancer.

We discuss the trial design, endpoints, results, safety concerns, and how it fits into current practice.

  continue reading

156 episodes